shortage of glp 1 FDA says GLP-1 drug tirzepatide is over Addressing GLP-1 Access and Adherence

The primary driver is the growing requirement for structured injection education, access navigation and treatment-start support

Galvano et al., 2009[17]

& nler-Gmta, A

Early treatment and specialist care can help manage risks and support better health outcomes

Although prior evidence primarily implicated semaglutide, our findings suggest a class effect

Figure 4: Opportunities Outside of Diabetes and Obesity for Incretin Mimetics As mentioned earlier, NASH is an area that has attracted a high level of manufacturer attention, as the liver disease is associated with metabolic syndrome and represents an area of large commercial opportunity with significant unmet medical need